Evolus, Inc. Common Stock (EOLS) — Analysis Summary
Evolus, Inc. Common Stock (EOLS) has a market cap of $523.78M with year-over-year revenue growth of +11.6%. Net margin stands at -17.4%. The stock trades at a P/E ratio of -15.3.
Key Takeaways
- Revenue changed +11.6% year-over-year
- Net margin of -17.4%
- P/E ratio of -15.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, EOLS posted revenue growth of +11.6% and trades at a P/E of -15.3.
Evolus, Inc. Common Stock (EOLS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -1.2x — earnings do not cover interest payments
Shareholder equity is negative, which can signal balance-sheet stress.
The latest filing shows negative free cash flow.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
353
Headquarters
NEWPORT BEACH, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.